TY - JOUR
T1 - Quality of life in patients with metastatic renal cell carcinoma
T2 - Assessment of long-term survivors
AU - Carmichael, Courtney
AU - Yuh, Bertram E.
AU - Sun, Virginia
AU - Lau, Clayton
AU - Hsu, Joann
AU - Saikia, Junmi
AU - Liu, Xueli
AU - Wilson, Timothy
AU - Ferrell, Betty
AU - Pal, Sumanta Kumar
N1 - Funding Information:
Dr Pal's efforts are supported by the NIH Loan Repayment Plan (LRP) and NIH , K12 2K12CA001727-16A1 .
PY - 2013/6
Y1 - 2013/6
N2 - Background: An emerging literature describes the potential for long-term survival with targeted agents, but the health-related quality of life (HR-QOL) in patients who receive chronic therapy with these agents is poorly defined. Methods: From an institutional database including 562 patients with renal cell carcinoma (RCC), patients were identified who (1) were alive 3 years beyond initiation of systemic therapy for metastatic renal cell carcinoma (mRCC) and (2) received a targeted therapy as a component of their treatment. European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 36 (QLQ-C30) and Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI-15) questionnaires were administered by telephone survey. Data from questionnaires were compared with historical estimates derived from pivotal studies evaluating targeted agents. Results: A total of 38 patients met eligibility criteria for the study, and 28 patients participated in the telephone survey. Most were male patients and had clear cell histologic type (75% for both). All patients had either good- or intermediate-risk disease by Heng criteria. The mean QLQ-C30 Global QOL score in the present cohort was higher than the mean score among patients evaluated at baseline in the phase III evaluations of pazopanib (73.5 vs. 65.8; P =.07) and everolimus (73.5 vs. 61.0; P =.007). The FKSI-15 score in the present cohort was similar to the mean score among patients evaluated at baseline in the phase III evaluation of sunitinib (45.1 and 46.5, respectively; P =.41). Conclusion: In this small pilot study, long-term survivors with mRCC who received targeted therapies appear to have an HR-QOL comparable to that of patients who participated in relevant phase III studies. Given the many emerging treatment options for mRCC, the HR-QOL of long-term survivors warrants greater attention.
AB - Background: An emerging literature describes the potential for long-term survival with targeted agents, but the health-related quality of life (HR-QOL) in patients who receive chronic therapy with these agents is poorly defined. Methods: From an institutional database including 562 patients with renal cell carcinoma (RCC), patients were identified who (1) were alive 3 years beyond initiation of systemic therapy for metastatic renal cell carcinoma (mRCC) and (2) received a targeted therapy as a component of their treatment. European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 36 (QLQ-C30) and Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI-15) questionnaires were administered by telephone survey. Data from questionnaires were compared with historical estimates derived from pivotal studies evaluating targeted agents. Results: A total of 38 patients met eligibility criteria for the study, and 28 patients participated in the telephone survey. Most were male patients and had clear cell histologic type (75% for both). All patients had either good- or intermediate-risk disease by Heng criteria. The mean QLQ-C30 Global QOL score in the present cohort was higher than the mean score among patients evaluated at baseline in the phase III evaluations of pazopanib (73.5 vs. 65.8; P =.07) and everolimus (73.5 vs. 61.0; P =.007). The FKSI-15 score in the present cohort was similar to the mean score among patients evaluated at baseline in the phase III evaluation of sunitinib (45.1 and 46.5, respectively; P =.41). Conclusion: In this small pilot study, long-term survivors with mRCC who received targeted therapies appear to have an HR-QOL comparable to that of patients who participated in relevant phase III studies. Given the many emerging treatment options for mRCC, the HR-QOL of long-term survivors warrants greater attention.
KW - Metastatic
KW - Quality of life
KW - Renal cell carcinoma
KW - Targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=84876988771&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84876988771&partnerID=8YFLogxK
U2 - 10.1016/j.clgc.2012.09.006
DO - 10.1016/j.clgc.2012.09.006
M3 - Article
C2 - 23058499
AN - SCOPUS:84876988771
SN - 1558-7673
VL - 11
SP - 149
EP - 154
JO - Clinical Genitourinary Cancer
JF - Clinical Genitourinary Cancer
IS - 2
ER -